Serveur d'exploration sur les dispositifs haptiques

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Asymmetrical olfactory acuity and neuroleptic treatment in schizophrenia

Identifieur interne : 007C18 ( Main/Exploration ); précédent : 007C17; suivant : 007C19

Asymmetrical olfactory acuity and neuroleptic treatment in schizophrenia

Auteurs : S. E. Purdon ; P. Flor-Henry [Canada]

Source :

RBID : ISTEX:BB6AABFDC91AA33BC678D96652290E9E4C584961

Descripteurs français

English descriptors

Abstract

Uni-rhinal olfactory acuity in schizophrenia was investigated in two experiments. The first assessed the presence of a predicted atypical asymmetry of nostril laterality and the second assessed the effect of antipsychotic treatment on the asymmetry. Although olfactory identification impairment has been well documented in schizophrenia, olfactory acuity has been neglected. This may be an oversight as cerebral structures of the mesial temporal lobe important to olfactory perception have often been implicated in the pathophysiology of schizophrenia and it is thus reasonable to postulate a primary impairment of olfactory acuity in schizophrenia. In addition, unmedicated patients with schizophrenia have exhibited asymmetrical laterality favouring the right over the left hemisphere in studies of visual, haptic, and auditory perception, and the few published prospective treatment studies have suggested a reversal of this asymmetry with first generation neuroleptic treatments. In experiment 1 a generalization of the perceptual asymmetry to olfactory acuity was examined by measurement of n-butanol olfactory thresholds with the Connecticut Chemosensory Perception Exam (CCPE) in an unmedicated sample of 17 patients with schizophrenia and 17 age, gender, and handedness matched normal controls. The patient sample showed an asymmetrical impairment of the left nostril that was not apparent in the normal control sample. In experiment 2, the CCPE was administered to a new sample of 10 patients with schizophrenia before and after neuroleptic treatment. The asymmetry observed in experiment 1 was replicated, and the relative advantage of the right nostril shifted to a relative advantage of the left nostril over the course of 8weeks of treatment. Results are discussed in relation to cerebral aspects of schizophrenia and potential implications to cognitive change from treatment.

Url:
DOI: 10.1016/S0920-9964(99)00212-1


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Asymmetrical olfactory acuity and neuroleptic treatment in schizophrenia</title>
<author>
<name sortKey="Purdon, S E" sort="Purdon, S E" uniqKey="Purdon S" first="S. E." last="Purdon">S. E. Purdon</name>
</author>
<author>
<name sortKey="Flor Henry, P" sort="Flor Henry, P" uniqKey="Flor Henry P" first="P." last="Flor-Henry">P. Flor-Henry</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:BB6AABFDC91AA33BC678D96652290E9E4C584961</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1016/S0920-9964(99)00212-1</idno>
<idno type="url">https://api.istex.fr/document/BB6AABFDC91AA33BC678D96652290E9E4C584961/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004596</idno>
<idno type="wicri:Area/Istex/Curation">004596</idno>
<idno type="wicri:Area/Istex/Checkpoint">002F57</idno>
<idno type="wicri:doubleKey">0920-9964:2000:Purdon S:asymmetrical:olfactory:acuity</idno>
<idno type="wicri:Area/Main/Merge">008304</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0466810</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001459</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000054</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001239</idno>
<idno type="wicri:doubleKey">0920-9964:2000:Purdon S:asymmetrical:olfactory:acuity</idno>
<idno type="wicri:Area/Main/Merge">008700</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10962224</idno>
<idno type="wicri:Area/PubMed/Corpus">001E27</idno>
<idno type="wicri:Area/PubMed/Curation">001E27</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001B91</idno>
<idno type="wicri:Area/Ncbi/Merge">000130</idno>
<idno type="wicri:Area/Ncbi/Curation">000130</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000130</idno>
<idno type="wicri:doubleKey">0920-9964:2000:Purdon S:asymmetrical:olfactory:acuity</idno>
<idno type="wicri:Area/Main/Merge">008227</idno>
<idno type="wicri:Area/Main/Curation">007C18</idno>
<idno type="wicri:Area/Main/Exploration">007C18</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Asymmetrical olfactory acuity and neuroleptic treatment in schizophrenia</title>
<author>
<name sortKey="Purdon, S E" sort="Purdon, S E" uniqKey="Purdon S" first="S. E." last="Purdon">S. E. Purdon</name>
<affiliation>
<wicri:noCountry code="subField">T5J 2J7 Canada</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Flor Henry, P" sort="Flor Henry, P" uniqKey="Flor Henry P" first="P." last="Flor-Henry">P. Flor-Henry</name>
<affiliation>
<wicri:noCountry code="subField">T5J 2J7 Canada</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Canada</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Schizophrenia Research</title>
<title level="j" type="abbrev">SCHRES</title>
<idno type="ISSN">0920-9964</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1999">1999</date>
<biblScope unit="volume">44</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="221">221</biblScope>
<biblScope unit="page" to="232">232</biblScope>
</imprint>
<idno type="ISSN">0920-9964</idno>
</series>
<idno type="istex">BB6AABFDC91AA33BC678D96652290E9E4C584961</idno>
<idno type="DOI">10.1016/S0920-9964(99)00212-1</idno>
<idno type="PII">S0920-9964(99)00212-1</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0920-9964</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Acuity</term>
<term>Adult</term>
<term>Antipsychotic Agents (pharmacology)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Asymmetry</term>
<term>Brain (vertebrata)</term>
<term>Central nervous system</term>
<term>Chemotherapy</term>
<term>Clinical investigation</term>
<term>Comparative study</term>
<term>Double-Blind Method</term>
<term>Experimental study</term>
<term>Female</term>
<term>Follow up study</term>
<term>Functional Laterality (drug effects)</term>
<term>Hemispheric specialization</term>
<term>Human</term>
<term>Humans</term>
<term>Laterality</term>
<term>Male</term>
<term>Neuroleptic</term>
<term>Olfaction</term>
<term>Olfaction Disorders (complications)</term>
<term>Perception</term>
<term>Prospective Studies</term>
<term>Psychotropic</term>
<term>Schizophrenia</term>
<term>Schizophrenia (complications)</term>
<term>Schizophrenia (drug therapy)</term>
<term>Sensory Thresholds (drug effects)</term>
<term>Smell (drug effects)</term>
<term>Treatment</term>
<term>UPSIT</term>
<term>acuity</term>
<term>asymmetry</term>
<term>laterality</term>
<term>neuroleptic.</term>
<term>olfaction</term>
<term>schizophrenia</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Olfaction Disorders</term>
<term>Schizophrenia</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Functional Laterality</term>
<term>Sensory Thresholds</term>
<term>Smell</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Schizophrenia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Prospective Studies</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Acuité</term>
<term>Asymétrie</term>
<term>Chimiothérapie</term>
<term>Encéphale</term>
<term>Etude comparative</term>
<term>Etude expérimentale</term>
<term>Etude longitudinale</term>
<term>Exploration clinique</term>
<term>Homme</term>
<term>Latéralité</term>
<term>Neuroleptique</term>
<term>Olfaction</term>
<term>Perception</term>
<term>Psychotrope</term>
<term>Schizophrénie</term>
<term>Spécialisation hémisphérique</term>
<term>Système nerveux central</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Homme</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Uni-rhinal olfactory acuity in schizophrenia was investigated in two experiments. The first assessed the presence of a predicted atypical asymmetry of nostril laterality and the second assessed the effect of antipsychotic treatment on the asymmetry. Although olfactory identification impairment has been well documented in schizophrenia, olfactory acuity has been neglected. This may be an oversight as cerebral structures of the mesial temporal lobe important to olfactory perception have often been implicated in the pathophysiology of schizophrenia and it is thus reasonable to postulate a primary impairment of olfactory acuity in schizophrenia. In addition, unmedicated patients with schizophrenia have exhibited asymmetrical laterality favouring the right over the left hemisphere in studies of visual, haptic, and auditory perception, and the few published prospective treatment studies have suggested a reversal of this asymmetry with first generation neuroleptic treatments. In experiment 1 a generalization of the perceptual asymmetry to olfactory acuity was examined by measurement of n-butanol olfactory thresholds with the Connecticut Chemosensory Perception Exam (CCPE) in an unmedicated sample of 17 patients with schizophrenia and 17 age, gender, and handedness matched normal controls. The patient sample showed an asymmetrical impairment of the left nostril that was not apparent in the normal control sample. In experiment 2, the CCPE was administered to a new sample of 10 patients with schizophrenia before and after neuroleptic treatment. The asymmetry observed in experiment 1 was replicated, and the relative advantage of the right nostril shifted to a relative advantage of the left nostril over the course of 8weeks of treatment. Results are discussed in relation to cerebral aspects of schizophrenia and potential implications to cognitive change from treatment.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Purdon, S E" sort="Purdon, S E" uniqKey="Purdon S" first="S. E." last="Purdon">S. E. Purdon</name>
</noCountry>
<country name="Canada">
<noRegion>
<name sortKey="Flor Henry, P" sort="Flor Henry, P" uniqKey="Flor Henry P" first="P." last="Flor-Henry">P. Flor-Henry</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/HapticV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007C18 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007C18 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Ticri/CIDE
   |area=    HapticV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:BB6AABFDC91AA33BC678D96652290E9E4C584961
   |texte=   Asymmetrical olfactory acuity and neuroleptic treatment in schizophrenia
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Mon Jun 13 01:09:46 2016. Site generation: Wed Mar 6 09:54:07 2024